Full-Time
Genetic testing for hereditary diseases
No salary listed
Senior, Expert
Nashville, TN, USA
In Person
Minimum 70% travel required.
Myriad Genetics focuses on providing genetic tests that help in the diagnosis and management of major diseases. Their tests are designed to identify hereditary cancer risks, skin cancer, prostate cancer, and rheumatoid arthritis, among others. The tests work by analyzing a person's genetic information to provide insights into their health risks, enabling early detection and personalized treatment plans. Myriad Genetics differentiates itself from competitors through its high accuracy in test results, secure management of personal data, and the clarity of the information provided, which supports patients in making informed healthcare decisions. The company's goal is to improve and save lives by delivering precise genetic insights that enhance patient care.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Salt Lake City, Utah
Founded
1991
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Flexible Work Hours
Myriad Genetics, Inc. (MYGN) showcases breakthrough MRD data and ai-driven cancer tools at ASCO 2025.
NEW YORK, NY / ACCESS Newswire / May 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws.
Myriad Genetics (NASDAQ:MYGN) announced it has appointed Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. MYGN, a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million, comprising (i) time-based restricted stock units (RSUs) equal to $2 million and (ii) performance-based restricted stock units (PSUs) equal to $1.75 million, in each case effective as of the first day of his employment. These equity awards are inducements material to Mr. Donnelly's entering into employment with Myriad Genetics in accordance with Nasdaq Listing Rule 5635(c)(4)
Myriad also announced that Mark S. Verratti, the compnay's current chief commercial officer, will be promoted to chief operating officer upon Raha's appointment.